The Impact of Acute Urinary Retention After Iodine-125 Prostate Brachytherapy on Health-Related Quality of Life

Roeloffzen, Ellen M.A.; Hinnen, Karel A.; Battermann, Jan J.; Monninkhof, Evelyn M.; van Roermund, Joep G.H.; van Gellekom, Marion P.R.; Frank, Steven J.; van Vulpen, Marco

doi:10.1016/j.ijrobp.2009.06.083

« Previous Next »International Journal of Radiation Oncology * Biology * Physics
Volume 77, Issue 5 , Pages 1322-1328, 1 August 2010

The Impact of Acute Urinary Retention After Iodine-125 Prostate Brachytherapy on Health-Related Quality of Life

Ellen M.A. Roeloffzen, M.D.
- Department of Radiation Oncology, University Medical Center Utrecht, Utrecht, The Netherlands
- Reprint requests to: Ellen Roeloffzen, M.D., Department of Radiation Oncology, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands. Tel: (+31) 887558800; Fax: (+31) 887555850
Karel A. Hinnen, M.D.
- Department of Radiation Oncology, University Medical Center Utrecht, Utrecht, The Netherlands
Jan J. Battermann, M.D., Ph.D.
- Department of Radiation Oncology, University Medical Center Utrecht, Utrecht, The Netherlands
Evelyn M. Monninkhof, Ph.D.
- Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands
Joep G.H. van Roermund, M.D.
- Department of Urology, University Medical Center Utrecht, Utrecht, The Netherlands
Marion P.R. van Gellekom, Ph.D.
- Department of Radiation Oncology, University Medical Center Utrecht, Utrecht, The Netherlands
Steven J. Frank, M.D.
- Department of Radiation Oncology, M. D. Anderson Medical Center, Houston, TX
Marco van Vulpen, M.D., Ph.D.
- Department of Radiation Oncology, University Medical Center Utrecht, Utrecht, The Netherlands

Received 15 May 2009; received in revised form 25 June 2009; accepted 29 June 2009. published online 24 November 2009.

Purpose

To evaluate the impact of acute urinary retention (AUR) in patients treated with ¹²⁵I prostate brachytherapy on short- and long-term health-related quality of life (HRQOL); and to assess whether pretreatment HRQOL has additional value in the prediction of AUR.

Methods and Materials

For 127 patients treated with ¹²⁵I brachytherapy for localized prostate cancer between December 2000 and June 2003, toxicity and HRQOL data were prospectively collected. Patients received a HRQOL questionnaire at five time points: before and 1 month, 6 months, 1 year, and 6 years after treatment. The questionnaire included the RAND-36 generic health survey, the cancer-specific European Organization for Research and Treatment of Cancer core questionnaire (EORTC QLQ-C30), the tumor-specific EORTC prostate cancer module (EORTC QLQ-PR25), and the American Urological Association (AUA) symptom index.

Results

Of 127 patients, 13 (10.2%) developed AUR. Patients with AUR had a significantly worse urinary QOL at all time points compared with patients without AUR. The mean difference over time (6 years) between both groups for the EORTC QLQ-PR25 urinary symptom score was 13.0 points (p < 0.001) and for the AUA urinary symptom score was 15.7 points (p = 0.001). Global QOL scores (EORTC QLQ-C30) over time for patients who developed AUR were significantly worse compared with patients without AUR (mean difference 6.7 points; p = 0.043). In multivariate logistic regression analysis, pretreatment International Prostate Symptom Score (p = 0.004) and neoadjuvant hormonal treatment (p = 0.034) were predictors of AUR. Quality of life did not have added predictive value.

Conclusion

Acute urinary retention after prostate brachytherapy has a significant negative impact on patient's HRQOL up to 6 years after treatment, in terms of both global QOL measures and urinary symptom scores. Furthermore, our results suggest limited value of pretreatment HRQOL measures for the prediction of AUR.

Acute urinary retention, Health-related quality of life, Prostate cancer, ¹²⁵I brachytherapy, EORTC QLQ-PR25